^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MQ710

    i
    Associations

    News

    Trials
    Company:
    Imvaq Therap
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    9ms
    A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer (clinicaltrials.gov)
    P1, N=5, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=56 --> 5
    Enrollment closed • Enrollment change • Combination therapy • Checkpoint inhibition
    |
    BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • MQ710
    almost2years
    A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer (clinicaltrials.gov)
    P1, N=56, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2025 --> May 2028 | Trial primary completion date: May 2025 --> May 2028
    Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition
    |
    BRAF (B-raf proto-oncogene)
    |
    PD-L1 expression • BRAF mutation
    |
    Keytruda (pembrolizumab) • MQ710
    almost2years
    A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer (clinicaltrials.gov)
    P1, N=56, Recruiting, Memorial Sloan Kettering Cancer Center
    New P1 trial • Combination therapy • Checkpoint inhibition
    |
    BRAF (B-raf proto-oncogene)
    |
    PD-L1 expression • BRAF mutation
    |
    Keytruda (pembrolizumab) • MQ710